• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Optimizing BTKi Treatment Strategies


The panelists provide perspectives on critical aspects of the CLL and SLL treatment landscape.

This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA, CPEL; Tara Graff, DO, MS; Ryan Jacobs, MD; Deborah Stephens, DO; Jennifer Woyach, MD.

The group discusses anticipated advancements in Bruton tyrosine kinase inhibitor (BTKi) therapy for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). A key goal is converting continuous BTKi treatment into time-limited approaches through combinations or stopping criteria based on deep responses. This could improve quality of life and reduce financial burdens compared with indefinite therapy.Incorporating assessment of minimal residual disease as a trigger for discontinuation is an exciting strategy being explored in trials.

The panelists highlight the potential of leveraging precision medicine through mutational profiling and cytogenetics to guide upfront BTKi selection and sequencing. This allows customization based on a patient’s molecular features rather than a one-size-fits-all approach. Expanding the options for noncovalent BTKis that can overcome specific resistance mutations will enable optimal treatment sequencing tailored to a patient’s mutational profile when disease relapse occurs.

Overall, the group is optimistic about integrating predictive biomarkers, combination strategies, and novel targeted agents to usher in an era of personalized BTKi therapy in CLL and SLL. This offers hope for maximizing treatment outcomes while minimizing toxicity burdens for patients.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

Related Videos
Ronesh Sinha, MD
Yuqian Liu, PharmD
Video 11 - "Social Burden and Goals of Therapy for Patients with Bronchiectasis"
Video 7 - "Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words"
dr monica li
dr lawrence eichenfield
Video 14 - "Achieving Equitable Representation in Clinical Studies"
Video 13 - "Measuring Implicit Bias"
Dr Michael Morse, Duke University
Video 10 - "Bronchiectasis Exacerbation Management"
Related Content
© 2024 MJH Life Sciences
All rights reserved.